Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib.
Dhruva
Nirav
N
Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Socinski
Mark A
MA
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001707:Biopsy, Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D000069347:Erlotinib Hydrochloride; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008577:Meningeal Neoplasms / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000556:secondary*; D008581:Meningitis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D011799:Quinazolines / Q000008:administration & dosage*; D018570:Risk Assessment; D014057:Tomography, X-Ray Computed
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride